Perrigo Confirms Filing for Generic Version of VANOS(R) (PR Newswire)

ALLEGAN, Mich., June 9 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application (ANDA) for Fluocinonide Cream 0.1%, a generic version of VANOS® Cream 0.1%. The Company believes that it is the first to file an ANDA with a Paragraph IV certification against VANOS®. VANOS® (fluocinonide) Cream 0.1% is a corticosteroid (steroid hormone) approved to relieve the inflammation and itching caused by certain skin conditions that respond to treatment with corticosteroids in patients 12 years of age or older, and had sales of approximately $27 million for the 12 months ended April 2008, as measured by Wolters Kluwer Health. Perrigo filed its ANDA for Fluocinonide Cream, 0.1% containing a Paragraph IV Certification with the U.S. Food & Drug Administration and... [read full story]